Syra Health Corp
Qualité des données : 100%
SYRA
OTC
Services
Business Services
0,31 €
▲
0,04 €
(16,04%)
Cap. Boursière: 3,71 M
Prix
0,31 €
Cap. Boursière
3,71 M
Fourchette du Jour
0,28 € — 0,32 €
Fourchette 52 Semaines
0,03 € — 0,32 €
Volume
74 340
Ouverture 0,29 €
Moyenne 50J / 200J
0,12 €
159,17% above
Moyenne 50J / 200J
0,09 €
236,58% above
Quick Summary
Points Clés
Negative free cash flow of -447 853,0
Capital efficient — spends only 0,00% of revenue on capex
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)-9,47%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-38,77%
En dessous de la moyenne du secteur (-15,95%)
ROIC-30,90%
Net Margin-12,40%
Op. Margin-12,51%
Sécurité
Debt / Equity
N/A
Current Ratio3,05
Interest Coverage-68,15
Valorisation
PE (TTM)
-4,14
En dessous de la moyenne du secteur (-1,17)
P/B Ratio1,68
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Services (502 pairs)
Comparaison Sectorielle
vs médiane du secteur Services (502 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -4,1 | -1,2 |
| P/B | 1,7 | 1,4 |
| ROE % | -38,8 | -16,0 |
| Net Margin % | -12,4 | -19,4 |
| Rev Growth 5Y % | — | 4,0 |
| D/E | — | 0,4 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -9,47% | Revenue Growth (3Y) | 14,46% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 7,23 M | Net Income (TTM) | -896 333,0 |
| ROE | -38,77% | ROA | -26,62% |
| Gross Margin | 34,43% | Operating Margin | -12,51% |
| Net Margin | -12,40% | Free Cash Flow (TTM) | -447 853,0 |
| ROIC | -30,90% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3,05 |
| Interest Coverage | -68,15 | Asset Turnover | 2,15 |
| Working Capital | 2,16 M | Tangible Book Value | 2,21 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -4,14 | Forward P/E | N/A |
| P/B Ratio | 1,68 | P/S Ratio | 0,51 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -12,08% | ||
| Market Cap | 3,71 M | Enterprise Value | 1,73 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,08 | Revenue / Share | 0,61 |
| FCF / Share | -0,04 | OCF / Share | -0,04 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,00% | FCF Conversion | 49,97% |
| SBC-Adj. FCF | -523 047 | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 7,23 M | 7,98 M | 5,52 M |
| Net Income | -896 333,0 | -3,76 M | -2,94 M |
| EPS (Diluted) | -0,08 | -0,50 | -0,60 |
| Gross Profit | 2,49 M | 1,65 M | 1,41 M |
| Operating Income | -904 324,0 | -3,76 M | -2,89 M |
| EBITDA | — | — | — |
| R&D Expenses | 67 840,0 | 585 146,0 | 240 048,0 |
| SG&A Expenses | 1,07 M | 1,45 M | 1,13 M |
| D&A | — | — | — |
| Interest Expense | 13 270,0 | 15 600,0 | 53 686,0 |
| Income Tax | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | 2,77 M | 3,68 M | 4,92 M |
| Total Liabilities | 674 739,0 | 800 761,0 | 910 072,0 |
| Shareholders' Equity | 2,10 M | 2,88 M | 4,01 M |
| Total Debt | — | — | — |
| Cash & Equivalents | 1,61 M | 2,40 M | 3,28 M |
| Current Assets | 2,74 M | 3,35 M | 4,78 M |
| Current Liabilities | 674 739,0 | 613 549,0 | 910 072,0 |
{"event":"ticker_viewed","properties":{"ticker":"SYRA","listing_kind":"stock","pathname":"/stocks/syra","exchange":"OTC","country":"US"}}